Sir Witty CEO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Andrew Witty CEO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Marc Dunoyer Global Head of Rare Diseases and Chairman of GSK Japan, CPA
Moncef Slaoui Chairman of Global RandD and Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee, Ph.D
GSK Diversification Suggestion
Use GSK to protect against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of GSK to be traded at $51.98 in 30 days
GSK Price and Market Media
The median price of GSK for the period between Sat, Nov 9, 2013 and Mon, Dec 9, 2013 is 52.6 with a coefficient of variation of 0.82. The daily time series for the period is distributed with a sample standard deviation of 0.43, arithmetic mean of 52.56, and mean deviation of 0.36. The Stock received substential amount of media coverage during this period.
GlaxoSmithKline plc [GSK] is traded on New York Stock Exchange in USA. It is located in Brentford, TW GS and employs 99,488 people. The company currently falls under 'Mega-Cap' category with total capitalization of 126.45 B. GlaxoSmithKline plc runs under Healthcare sector within Drug Manufacturers - Major industry. This company has 2.41 B outstanding shares of which 3.02 M shares are currently shorted by investors with about 2.3 days to cover shorted positions.
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, overthecounter medicines, and healthrelated consumer solutions worldwide. more
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory